SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aarti Drugs rises as its arm incorporates overseas wholly owned subsidiary

28 Nov 2024 Evaluate

Aarti Drugs is currently trading at Rs. 463.00, up by 6.50 points or 1.42% from its previous closing of Rs. 456.50 on the BSE.

The scrip opened at Rs. 459.00 and has touched a high and low of Rs. 464.15 and Rs. 457.00 respectively. So far 304 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 634.90 on 27-Aug-2024 and a 52 week low of Rs. 430.00 on 28-Mar-2024.

Last one week high and low of the scrip stood at Rs. 464.15 and Rs. 441.00 respectively. The current market cap of the company is Rs. 4166.48 crore.

The promoters holding in the company stood at 55.64%, while Institutions and Non-Institutions held 10.34% and 34.02% respectively.

Aarti Drugs’ subsidiary -- Pinnacle Chile SpA has incorporated an overseas wholly owned subsidiary in the name of Pharma Go SpA for marketing the formulation drugs and participating in tender and private market in Chile. Its business is in line with the business of its holding companies. The newly incorporated company i.e. Pharma Go SpA becomes a step-down subsidiary of the Aarti Drugs.

Aarti Drugs is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science.


Aarti Drugs Share Price

394.90 19.85 (5.29%)
04-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.10
Dr. Reddys Lab 1287.95
Cipla 1334.85
Zydus Lifesciences 901.65
Lupin 2350.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×